Hematopoietic stem cell transplant is a potentially curative treatment option for a variety of benign and malignant hematological disorders. In the last four decades, major advancements have been made in this field with respect to donor selection, conditioning regimens, treatment of complications (e.g., graft versus host disease), and long-term posttransplant care to improve the quality of life of the survivors. However, challenges still exist such as treatment of opportunistic infections, toxicity of conditioning regimens, psychosocial issues, and, in developing countries, the cost of the procedure.

This special issue aims to publish original research articles and reviews that address the issue of emerging infections in hematopoietic stem cell transplant patients in developing countries. The special issue will focus on topics such as rare and viral infections in transplant patients, the incidence and outcome of rare fungal infections, carbapenem resistant bacterial pathogens, and the role of hospital infection control committees for transplant recipients.

Potential topics include but are not limited to the following:

• Emerging opportunistic infections and their effects on bone marrow transplant recipients
• Rare and emerging viral infections in hematopoietic stem cell transplant recipients
• Incidence and outcome of rare blood and central line fungal isolates in bone marrow transplants
• Should EBV testing be mandatory for hematopoietic stem cell transplant donors and recipients?
• Outcome of carbapenem-resistant Enterobacteriaceae-associated bacteremia in hematopoietic stem cell transplant patients
• How hospital infection control committees can contribute towards quality assurance for bone marrow transplant units